RE: PAMAM-OH nanoparticles
Olinto,
Hing et al reported using mixed-effect modeling instead of fixed effects
modeling to characterize data (and may reduce parameter bias). However, this
method still does not characterize between animal variability.
Matt.
Hing, J. P.; Woolfrey, S. G.; Greenslade, D. & Wright, P. M.
Is mixed effects modeling or naïve pooled data analysis preferred for the
interpretation of single sample per subject toxicokinetic data?
J Pharmacokinet Pharmacodyn, Department of Anaesthesia, University of Newcastle
upon Tyne and Alnwick Research Centre, Sanofi, Alnwick, Northumberland., 2001,
28, 193-210
Quoted reply history
From: [email protected] [mailto:[email protected]] On
Behalf Of Olinto Linares
Sent: Thursday, June 02, 2011 12:04 PM
To: [email protected]
Cc: [email protected]
Subject: [NMusers] PAMAM-OH nanoparticles
Dears NMusers
PAMAM Nanoparticles used as anticancer drug carrier.
During a biodistribution study 5 mice were sacrificed at each sample time, 5,
30, 60, 120 minutes, and 6, and 24 hours, after a bolus infusion of 50mg/kg of
PAMAM-OH.
We are interested in the PAMAM-OH kinetics.
Can we apply population pharmacokinetics analysis on these types of data? (i.e
grouping the data as if they came from only 5 mice that were sampled at those
times)?
looking for ideas, suggestions
________________________________
This e-mail (including any attachments) is confidential and may be legally
privileged. If you are not an intended recipient or an authorized
representative of an intended recipient, you are prohibited from using, copying
or distributing the information in this e-mail or its attachments. If you have
received this e-mail in error, please notify the sender immediately by return
e-mail and delete all copies of this message and any attachments.
Thank you.